Home > Press > Keystone Nano selected by National Cancer Institute to participate in BIO
 |
Abstract:
Keystone Nano is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in BIO 2016, being held in San Francisco in June. Keystone Nano will participate in the bio-partnering program and the exhibit as a part of the NCI delegation of emerging cancer companies.
Keystone Nano selected by National Cancer Institute to participate in BIO
State College, PA | Posted on March 23rd, 2016BIO’s International Convention has been a leading meeting worldwide for biotechnology and pharmaceutical companies for more than two decades. The meeting features tens of thousands of participants seeking to build cooperative business opportunities.
Keystone Nano is an emerging biopharmaceutical company developing three independent but interrelated nanotechnology therapeutic platforms for the treatment of cancer and infectious disease:
Ceramide Nanoliposome - a novel therapy that will begin human testing in August 2016 with a $2.0 million grant from the National Cancer Institute.
Photo Immuno Nano Therapy -- a non-toxic therapy for the treatment of cancer that combines immune up regulation and photo therapy utilizing NanoJackets. Keystone’s NanoJackets are biocompatible calcium phosphate nanoparticles that protect the active ingredient in serum and deliver it to the interior of the cell. They may be actively or passively targeted to specific cell types.
RNA-NanoJackets -- New therapies for the treatment of cancer and infectious disease using siRNA, mRNA and miRNA via NanoJackets.
At BIO, KN will be seeking partners interested in Ceramide NanoLiposome and the improved delivery of RNA as well as other anti-cancer compounds using NanoJackets.
####
About Keystone Nano
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing NanoJacket products and Ceramide NanoLiposome for a variety of medical applications. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
For more information, please click here
Contacts:
Jeff Sirianni
Copyright © Keystone Nano
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
Cancer
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
New-Contracts/Sales/Customers
Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020
GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||